Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Omeros (OMER) Long-Term Debt Issuances (2011 - 2020)

Omeros recorded quarterly Long-Term Debt Issuances of $225.0 million in Q3 2020, up 35.99% quarter-over-quarter from $165.4 million in Q4 2018.

Omeros' Long-Term Debt Issuances history runs 6 years deep, the most recent figure standing at $225.0 million for Q3 2020.

  • In Q3 2020, Long-Term Debt Issuances changed N/A year-over-year to $225.0 million; the TTM figure through Sep 2020 stood at $390.4 million (changed N/A YoY), while the FY2020 annual figure was $225.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $225.0 million for Q3 2020 at Omeros, up from $165.4 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $225.0 million in Q3 2020 to a low of -$19.9 million in Q4 2016.
  • A 3-year average of $123.5 million and a median of $165.4 million in 2018 frame the typical range for Long-Term Debt Issuances.
  • On a YoY basis, Long-Term Debt Issuances climbed as much as 139.73% in 2016 and fell as far as 139.73% in 2016.
  • Omeros' Long-Term Debt Issuances stood at -$19.9 million in 2016, then jumped by 932.91% to $165.4 million in 2018, then soared by 35.99% to $225.0 million in 2020.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $225.0 million, $165.4 million, and -$19.9 million for Q3 2020, Q4 2018, and Q4 2016 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 225.00 Mn
Sep 30, 2020 225.00 Mn
Dec 31, 2018 165.45 Mn
Dec 31, 2018 165.45 Mn
Dec 31, 2016 -19.86 Mn
Dec 31, 2016 -19.86 Mn
Dec 31, 2015 50.00 Mn
Dec 31, 2015 50.00 Mn
Dec 31, 2014 19.30 Mn
Dec 31, 2014 19.30 Mn
Jun 30, 2014 -1,000.00
Jun 30, 2014 -1,000.00
Mar 31, 2014 12.70 Mn
Mar 31, 2014 12.70 Mn
Mar 31, 2011 9.94 Mn
Mar 31, 2011 9.94 Mn